This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...
Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo. Patients with clear cell renal cell carcinoma (ccRCC) experienced ...
Merck's Keytruda demonstrates superior overall survival with adjuvant therapy compared to placebo in kidney cancer patients. Merck's KEYNOTE-564 trial is the first Phase 3 adjuvant trial to show ...
Zacks Investment Research on MSN
EXEL collaborates with MRK for late-stage colorectal cancer study
Exelixis EXEL announced a clinical development collaboration with pharma giant Merck & Co. MRK to evaluate its pipeline candidate, zanzalintinib, in combination with subcutaneous Keytruda Qlex in the ...
As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...
Doctors monitor Keytruda’s effectiveness using imaging tests like CT or MRI scans to check tumor size. (Sometimes tumors may appear larger initially due to a phenomenon called pseudoprogression.) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results